Standard chemotherapy for metastatic breast cancer
Tashiro, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 246-253
2000
ISSN/ISBN: 0047-1852 PMID: 11026002 Document Number: 523547
Document emailed within 1 workday
Related Documents
Leonard, R.C. 1998: High-dose chemotherapy in metastatic breast cancer Lancet 351(9107): 986Chan, S. 1997: Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy Oncology 11(8 Suppl 8: 19-24
Kashiwagi, S.; Ishihara, S.; Asano, Y.; Kurata, K.; Tauchi, Y.; Tokumoto, M.; Morisaki, T.; Noda, S.; Kawajiri, H.; Takashima, T.; Onoda, N.; Hirakawa, K. 2014: Eribulin chemotherapy after taxane treatment in advanced metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1951-1953
Creech, R.H.; Catalano, R.B.; Dierks, K.M.; Shah, M.K. 1984: Phase Ii study of mitolactol in chemotherapy-refractory metastatic breast cancer Cancer Treatment Reports 68(12): 1499-1501
Manni, A.; Trujillo, J.E.; Pearson, O.H. 1980: Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival Cancer Treatment Reports 64(1): 111-116
Vogel, C.L. 1995: Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review Seminars in Oncology 22(2 Suppl 5: 61-65
Umsawasdi, T.; Nilprabhassorn, P. 1978: Combination chemotherapy with cyclophosphamide (NSC-26 271), methotrexate (NSC-740), and prednisolone (NSC-9 900) (CMP protocol), for metastatic breast cancer Journal of the Medical Association of Thailand 61(3): 158-161
Kitagawa, D.; Saji, S. 2007: The differences of standard therapy for breast cancer between Europe/America and Japan--chemotherapy, operation,and radiotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(5): 690-693
Pannuti, F.; Di Marco, A.R.; Rossi, A.P.; Rocchetta, G.; Rubino, I.; Giovannini, M.; Fruet, F. 1981: Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary results Panminerva Medica 23(2): 93-96
Shinagawa, K.; Ogawa, M.; Horikoshi, N.; Inoue, K.; Mukaiyama, T.; Fukutani, H.; Tabata, M.; Hirano, A.; Mizunuma, N. 1989: A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy Gan no Rinsho. Japan Journal of Cancer Clinics 35(5): 581-586
Nerich, V.; Bazan, F.; Compagnat, F.; Dobi, E.; Villanueva, C.; Chaigneau, Lïc.; Perrin, S.; Voidey, A.; Pivot, X.; Limat, S. 2012: First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis Anticancer Research 32(8): 3547-3552
Pannuti, F.; Rossi, A.P.; Di Marco, A.R.; Fruet, F.; Lelli, G.; Strocchi, E.; Rocchetta, G.; Piana, E.; Martoni, A. 1981: Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot study Panminerva Medica 23(1): 25-28
Stemmler, H.J.; Salat, C.; Lindhofer, H.; Menzel, H.; Untch, M.; Kahlert, S.; Konecny, G.; Sauer, H.; Ledderose, G.; Heinemann, V.; Kolb, H.J. 2005: Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study Anticancer Research 25(4): 3047-3054
Halim, A.; Wahba, H. 2012: Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 254-258
Chen, T.L.; Passos-Coelho, J.L.; Noe, D.A.; Kennedy, M.J.; Black, K.C.; Colvin, O.M.; Grochow, L.B. 1995: Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation Cancer Research 55(4): 810-816
Muthalib, A.; Darwis, I.; Prayogo, N.; Sutjipto 2000: Preliminary results of multicenter phase Ii trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 498-504
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Bearman, S.I.; Shpall, E.J.; Jones, R.B.; Cagnoni, P.J.; Ross, M. 1996: High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer Seminars in Oncology 23(1 Suppl 2: 60-67
Fetting, J.H.; Siminoff, L.A.; Piantadosi, S.; Abeloff, M.D.; Damron, D.J.; Sarsfield, A.M. 1990: Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 8(9): 1476-1482
Chagpar, A.B. 2007: Insights into the management of locally advanced, inflammatory, and metastatic breast cancer: highlights from the 2007 Louisville Breast Cancer Update Journal of the Kentucky Medical Association 105(11): 559-560